Open AccessRifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
Author(s) -
Tamai Yasuyuki,
Iwasa Motoh,
Eguchi Akiko,
Shigefuku Ryuta,
Kamada Yoshihiro,
Miyoshi Eiji,
Takei Yoshiyuki
Publication year - 2021
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12596
Subject(s) - rifaximin , hyperammonemia , hepatic encephalopathy , inflammation , medicine , gastroenterology , encephalopathy , cirrhosis , biology , antibiotics , microbiology and biotechnology
Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10‐7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.